Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria.

Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.

Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline data was reported.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.

Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.

Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline data was reported.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.

Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.

The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. "Atorvastatin Unknown Dosage" arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.

Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose day; Week 12 dose: dose taken at Week 12

The analysis set included all participants who received at least 1 dose of atorvastatin. "Atorvastatin Unknown Dosage" did not have Week 12 dose. Number analyzed refers to number of participants evaluable for specified category.

Daily dose was calculated by total dose divided by the total days of receiving atorvastatin.

The analysis set included all participants who received at least 1 dose of atorvastatin and evaluable for specified category (daily dose).

Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose; Week 12 dose: dose taken at Week 12 according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

Daily dose was calculated by total dose divided by the total days of receiving atorvastatin according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. The AEs were categorized by the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin.

AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death according to the CVD risk stratification. Low-risk: 10 years CV risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range according to the CVD risk stratification. Low-risk: 10 years CV risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported according to the CVD risk stratification. Low-risk: 10 years CV risk <5%; Moderate-risk: 10 years CVD risk 5%~10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10%~15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.

Percentage of participants who dropped out of the study and reasons for discontinuation were summarized overall.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.

Percentage of participants who dropped out of the study and reasons for discontinuation were summarized by the CVD risk stratification. Low-risk: 10 years CVD risk <5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.

The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. "Atorvastatin Unknown Dosage" arm within each CVD risk level was exclude since incomplete information on medication.